HUTCHMED (China) Limited
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- HUTCHMED (China) Limited is an innovative commercial-stage biopharmaceutical company specializing in the discovery, development, and commercialization of targeted therapeutics and immunotherapies primarily for cancer and immunological diseases. The company’s main products include oncology and immunology drugs such as FRUZAQLA® (fruquintinib), a targeted therapy for colorectal cancer marketed in over 30 countries through its partner Takeda, and savolitinib (ORPATHYS®), a selective oral MET inhibitor for non-small cell lung cancer, developed in collaboration with AstraZeneca. HUTCHMED’s product portfolio also encompasses antibody-targeted therapy conjugates (ATTCs), combining antibodies with targeted therapeutics, with new clinical candidates expected to enter trials in late 2025. The company operates through its Oncology/Immunology segment, focused on drug discovery and commercialization, alongside other ventures including the manufacture, sale, and distribution of prescription drugs and healthcare products primarily in China. HUTCHMED was founded in 2000 and is headquartered in Hong Kong. It conducts global clinical development and commercialization activities, with significant operations in China, the US, Europe, and Japan. The company maintains partnerships for commercial and clinical development, including licensing arrangements with multinational pharmaceutical companies such as Takeda and AstraZeneca. In recent strategic developments, HUTCHMED completed a $608 million divestment of a 45% equity interest in its non-core joint venture Shanghai Hutchison Pharmaceuticals (SHPL) to focus on its core business of innovative drug development, specifically its antibody-targeted therapy conjugate platform. This divestment occurred in early 2025 and is intended to fund advancement in its core oncology pipeline. HUTCHMED also reported significant sales growth in oncology products in 2024, with FRUZAQLA® achieving over $290 million in ex-China sales, and expanded its commercial reach globally. The company launched new clinical studies and expanded indications for its key therapies, including positive phase II results for savolitinib in combination with osimertinib for lung cancer. HUTCHMED continues to enhance its pipeline with new ATTC platform candidates and is preparing for additional product launches, including sovleplenib for idiopathic thrombocytopenic purpura in China. Overall, HUTCHMED leverages in-house research and a broad clinical pipeline in oncology and immunology with robust commercialization efforts and strategic global partnerships to drive growth and innovation in biopharmaceuticals. The company has around 1,800 employees and remains committed to expanding its global footprint while focusing on advanced therapeutic modalities and targeted therapies. This description integrates HUTCHMED’s main products, geographic reach, founding, and headquarters details, with the latest changes including its 2025 divestment of SHPL, pipeline advancements, drug launches, and strong sales performance in oncology therapeutics.
Company News
HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal
HUTCHMED shares jump 17% on US$1.3 billion GSK cancer drug deal
HUTCHMED (China) signs licensing deal with GSK for experimental solid tumour drug
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
Workday Named a Leader in 2026 Gartner® Magic Quadrant™ for Cloud HCM Suites for 1,000+ Employee Enterprises for Eleventh Consecutive Year
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma
Oracle Named a Leader in the 2026 Gartner® Magic Quadrant™ for Supply Chain Management Suites
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
HUTCHMED shares rise as lung cancer drug trial hits key targets
HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO®
Oracle Adds New Fusion Agentic Applications and AI Agents to Help Organizations Improve Talent Management
HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call Transcript
HUTCHMED H1 Earnings Call Highlights
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts
AI Solution Providers Shift From AI Features to AI-Enabled Execution